Medicare Rx May Necessitate Drug Comparison Studies In Early Development
Executive Summary
Manufacturers are conducting comparative efficacy analyses in the early stages of drug development to anticipate how their products' value will be judged as a result of the Medicare Modernization Act, Sanofi-Aventis Director-Public Policy Jean-Paul Gagnon told the Pharmaceutical Marketing Congress Sept. 12 in Philadelphia
You may also be interested in...
PhRMA’s Evidence-Based Medicine Principles Emphasize Individual Decisions
The Pharmaceutical Research & Manufacturers of America's principles for the use of evidence-based medicine emphasize that such data be used to "empower" patients and physicians
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials